111 related articles for article (PubMed ID: 15064943)
21. The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents.
Ries M; Ramaswami U; Parini R; Lindblad B; Whybra C; Willers I; Gal A; Beck M
Eur J Pediatr; 2003 Nov; 162(11):767-72. PubMed ID: 14505049
[TBL] [Abstract][Full Text] [Related]
22. FABRY'S DISEASE: CLASSIFICATION AS A SPHINGOLIPIDOSIS AND PARTIAL CHARACTERIZATION OF A NOVEL GLYCOLIPID.
SWEELEY CC; KLIONSKY B
J Biol Chem; 1963 Sep; 238():3148-50. PubMed ID: 14081947
[No Abstract] [Full Text] [Related]
23. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study.
Weidemann F; Breunig F; Beer M; Sandstede J; Turschner O; Voelker W; Ertl G; Knoll A; Wanner C; Strotmann JM
Circulation; 2003 Sep; 108(11):1299-301. PubMed ID: 12952834
[TBL] [Abstract][Full Text] [Related]
24. Enzyme replacement therapy in Fabry disease: clinical implications.
Breunig F; Knoll A; Wanner C
Curr Opin Nephrol Hypertens; 2003 Sep; 12(5):491-5. PubMed ID: 12920395
[TBL] [Abstract][Full Text] [Related]
25. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype.
Nakao S; Kodama C; Takenaka T; Tanaka A; Yasumoto Y; Yoshida A; Kanzaki T; Enriquez AL; Eng CM; Tanaka H; Tei C; Desnick RJ
Kidney Int; 2003 Sep; 64(3):801-7. PubMed ID: 12911529
[TBL] [Abstract][Full Text] [Related]
26. Enzyme replacement therapy in an adolescent with Fabry disease.
Illsinger S; Luecke T; Langen H; Das AM
Eur J Pediatr; 2003 Jul; 162(7-8):522-523. PubMed ID: 12733069
[No Abstract] [Full Text] [Related]
27. Fabry disease: diagnosis and treatment.
Breunig F; Weidemann F; Beer M; Eggert A; Krane V; Spindler M; Sandstede J; Strotmann J; Wanner C
Kidney Int Suppl; 2003 May; (84):S181-5. PubMed ID: 12694340
[TBL] [Abstract][Full Text] [Related]
28. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy.
Desnick RJ; Brady R; Barranger J; Collins AJ; Germain DP; Goldman M; Grabowski G; Packman S; Wilcox WR
Ann Intern Med; 2003 Feb; 138(4):338-46. PubMed ID: 12585833
[TBL] [Abstract][Full Text] [Related]
29. Enzyme replacement therapy in Anderson-Fabry's disease: beneficial clinical effect on vital organ function.
De Schoenmakere G; Chauveau D; Grünfeld JP
Nephrol Dial Transplant; 2003 Jan; 18(1):33-5. PubMed ID: 12480957
[TBL] [Abstract][Full Text] [Related]
30. Natural history and treatment of renal involvement in Fabry disease.
Branton M; Schiffmann R; Kopp JB
J Am Soc Nephrol; 2002 Jun; 13 Suppl 2():S139-43. PubMed ID: 12068026
[No Abstract] [Full Text] [Related]
31. Renal pathology in Fabry disease.
Alroy J; Sabnis S; Kopp JB
J Am Soc Nephrol; 2002 Jun; 13 Suppl 2():S134-8. PubMed ID: 12068025
[No Abstract] [Full Text] [Related]
32. Renal transplantation in patients with Fabry disease.
Sessa A; Meroni M; Battini G; Maglio A; Nebuloni M; Tosoni A; Panichi V; Bertagnolio B
Nephron; 2002 Jun; 91(2):348-51. PubMed ID: 12053080
[TBL] [Abstract][Full Text] [Related]
33. Renal ultrastructural findings in Anderson-Fabry disease.
Sessa A; Toson A; Nebuloni M; Pallotti F; Giordano F; Battini G; Maglio A; Meroni M; Calconi G; Bertolone G; Gatti P
J Nephrol; 2002; 15(2):109-12. PubMed ID: 12018625
[TBL] [Abstract][Full Text] [Related]
34. Advances in the management of Anderson-Fabry disease: enzyme replacement therapy.
Pastores GM; Thadhani R
Expert Opin Biol Ther; 2002 Mar; 2(3):325-33. PubMed ID: 11890871
[TBL] [Abstract][Full Text] [Related]
35. Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course.
Branton MH; Schiffmann R; Sabnis SG; Murray GJ; Quirk JM; Altarescu G; Goldfarb L; Brady RO; Balow JE; Austin Iii HA; Kopp JB
Medicine (Baltimore); 2002 Mar; 81(2):122-38. PubMed ID: 11889412
[No Abstract] [Full Text] [Related]
36. Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement.
Moore DF; Altarescu G; Ling GS; Jeffries N; Frei KP; Weibel T; Charria-Ortiz G; Ferri R; Arai AE; Brady RO; Schiffmann R
Stroke; 2002 Feb; 33(2):525-31. PubMed ID: 11823664
[TBL] [Abstract][Full Text] [Related]
37. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males.
MacDermot KD; Holmes A; Miners AH
J Med Genet; 2001 Nov; 38(11):750-60. PubMed ID: 11694547
[TBL] [Abstract][Full Text] [Related]
38. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease.
Eng CM; Guffon N; Wilcox WR; Germain DP; Lee P; Waldek S; Caplan L; Linthorst GE; Desnick RJ;
N Engl J Med; 2001 Jul; 345(1):9-16. PubMed ID: 11439963
[TBL] [Abstract][Full Text] [Related]
39. Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy.
Frustaci A; Chimenti C; Ricci R; Natale L; Russo MA; Pieroni M; Eng CM; Desnick RJ
N Engl J Med; 2001 Jul; 345(1):25-32. PubMed ID: 11439944
[No Abstract] [Full Text] [Related]
40. Enzyme replacement therapy in Fabry disease: a randomized controlled trial.
Schiffmann R; Kopp JB; Austin HA; Sabnis S; Moore DF; Weibel T; Balow JE; Brady RO
JAMA; 2001 Jun; 285(21):2743-9. PubMed ID: 11386930
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
